This document is an excerpt from the EUR-Lex website
Document 22023D1374
Decision of the EEA Joint Committee No 114/2020 of 6 August 2020 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/1374]
Decision of the EEA Joint Committee No 114/2020 of 6 August 2020 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/1374]
Decision of the EEA Joint Committee No 114/2020 of 6 August 2020 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/1374]
PUB/2022/1379
OJ L 172, 6.7.2023, p. 41–41
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
Date of entry into force unknown (pending notification) or not yet in force.
|
6.7.2023 |
EN |
Official Journal of the European Union |
L 172/41 |
DECISION OF THE EEA JOINT COMMITTEE No 114/2020
of 6 August 2020
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/1374]
THE EEA JOINT COMMITTEE,
Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,
Whereas:
|
(1) |
Regulation (EU) 2020/1043 of the European Parliament and of the Council of 15 July 2020 on the conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease (COVID-19) (1) is to be incorporated into the EEA Agreement. |
|
(2) |
Annex II to the EEA Agreement should therefore be amended accordingly, |
HAS ADOPTED THIS DECISION:
Article 1
The following point is inserted after point 19 (Commission Implementing Regulation (EU) No 699/2014) of Chapter XIII of Annex II to the EEA Agreement:
|
‘20. |
32020 R 1043: Regulation (EU) 2020/1043 of the European Parliament and of the Council of 15 July 2020 on the conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease (COVID-19) (OJ L 231, 17.7.2020, p. 12).’ |
Article 2
The text of Regulation (EU) 2020/1043 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
Article 3
This Decision shall enter into force on 6 August 2020, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).
Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.
Done at Brussels, 6 August 2020.
For the EEA Joint Committee
The President
Sabine MONAUNI
(1) OJ L 231, 17.7.2020, p. 12.
(*1) No constitutional requirements indicated.